In continuation of our recent report on the in vitro activity of sandalwood essential oils and their major components, the sesquiterpenes ()-α- and -β-santalols, against the pathogenic fungus , causative agent of the neglected tropical disease eumycetoma, we have now tested these isolated constituents, as well as native Royal Hawaiian sandalwood essential oil obtained from , for in vivo activity in a model system using infected larvae. Besides confirming the superior activity of ()-α-santalol over the ()β-isomer and the crude essential oil in two further strains of in vitro, the former compound also turned out to extend the lifespan of the infected larvae significantly, in contrast to ()-β-santalol, the total oil, or the antifungal drug itraconazole. The present findings not only characterize ()-α-santalol as a natural compound with promising in vivo activity against eumycetoma but also inspire further studies as a potential for novel, more effective therapy and warranting further studies to understand its mechanism of action and potential clinical applications.
Keywords: (Z)-α-santalol, (Z)-β-santalol, Galleria mellonella, Madurella mycetomatis, Royal Hawaiian sandalwood, Santalum paniculatum, eumycetoma, sandalwood essential oil
Molecules (Basel, Switzerland)
Journal Article
English
41157109
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.